Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Feb 15, 2024; 15(2): 137-141
Published online Feb 15, 2024. doi: 10.4239/wjd.v15.i2.137
Published online Feb 15, 2024. doi: 10.4239/wjd.v15.i2.137
Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control
Ke-Xin Zhang, Cheng-Xia Kan, Fang Han, Jing-Wen Zhang, Xiao-Dong Sun, Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China
Author contributions: All the authors contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: The authors declare no conflict-of-interests in preparing this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Dong Sun, PhD, Chief Physician, Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, No. 2428 Yuhe Road, Weifang 261031, Shandong Province, China. xiaodong.sun@wfmc.edu.cn
Received: November 25, 2023
Peer-review started: November 25, 2023
First decision: December 12, 2023
Revised: December 14, 2023
Accepted: January 16, 2024
Article in press: January 16, 2024
Published online: February 15, 2024
Peer-review started: November 25, 2023
First decision: December 12, 2023
Revised: December 14, 2023
Accepted: January 16, 2024
Article in press: January 16, 2024
Published online: February 15, 2024
Core Tip
Core Tip: Sodium-glucose cotransporter-2 inhibitors like empagliflozin offer cardioprotective benefits that extend beyond blood glucose control, improving heart function and reducing failure-related hospitalizations. Ongoing research is essential to elucidate the underlying mechanisms, potentially revolutionizing heart failure treatment across various patient profiles.